Hypermethylation of p16 gene promoter correlates with loss of p16 expression that results in poorer prognosis in esophageal squamous cell carcinomas

Diseases of the Esophagus

Volumn 21, Issue 2, 2008, Pages 125-131

  Fujiwara, S ^a   Noguchi, T ^a   Takeno, S ^a   Kimura, Y ^a   Fumoto, S ^a   Kawahara, K ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Esophagus; Methylation; P16; Prognosis; Squamouscell carcinoma

Indexed keywords

BISULFITE; GENOMIC DNA; PROTEIN P16;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA EXTRACTION; DNA MODIFICATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS TUMOR; FEMALE; GENETIC CORRELATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN METHYLATION; STATISTICAL SIGNIFICANCE; TISSUE SECTION;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DNA METHYLATION; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION; GENES, P16; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS (GENETICS);

EID: 39049090370     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2007.00735.x     Document Type: Article

References (38)

1. Ando N, Iizuki T, Ide H et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: A Japan clinical oncology group study-JCOG9204. J Clin Oncol 2003; 21: 4592-6.
2. Tachibana M, Yoshimura H, Kinugasa S et al. Postoperative chemotherapy vs. chemoradiotherapy for thoracic esophageal cancer: A prospective randomized clinical trial. Eur J Surg Oncol 2003; 29: 580-7.
3. Bidoli P, Bajetta E, Stani SC et al. Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus. Cancer 2002; 94: 352-61.
4. Merlo A, Herman J G, Mao L et al. 5′CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/ CDKN/MTS1 in human cancers. Nat Med 1995; 1: 686-92.
5. Bird A P. CpG-rich islands and the function of DNA methylation. Nature 1986; 321: 209-13.
6. Muller H M, Widschwendter A, Fiegl H et al. DNA methylation in serum of breast cancer patients: An independent prognostic marker. Cancer Res 2003; 63: 7641-5.
7. Jarmalaite S, Kannio A, Anttila S, Lazutka J R, Husgafvel-Pursiaimen K. Abberant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer. Int J Cancer 2003; 106: 913-18.
8. Kand G H, Lee S, Lee H J, Hwang K S. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol 2004; 202: 233-40.
9. Viswanathan M, Tsuchida N, Shanmugan G. Promoter hypermethylation profile of tumor-associated genes p16, p15 hMLH1 and E-cadherin in oral squamous cell carcinoma. Int J Cancer 2003; 105: 41-6.
10. 6 -methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 2001; 61: 939-42.
11. Noguchi T, Takeno S, Kimura Y et al. FHIT expression and hyper methylation in esophageal squamous cell carcinoma. Int J Mol Med 2003; 11: 441-7.
12. Tanaka H, Shimada Y, Harada H et al. Methylation of the 5′-CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res 1998; 58: 3429-34.
13. Riese U, Dahse R, Fiedler W et al. Tumor suppressor gene p16 (CDKN2A) mutation status and promoter inactivation in head and neck cancer. Int J Mol Med 1999; 4: 61-5.
14. Ueki T, Toyota M, Sohn T et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 2000; 60: 1835-9.
15. Wong D J, Foster S A, Galloway D A, Reid B J. Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M0 growth arrest. Mol Cell Biol 1999; 19: 5642-51.
16. Laird P W, Jaenisch R. The role of DNA methylation in cancer genetics and epigenetics. Ann Rev Genet 1996; 30: 441-64.
17. Cordon-Cardo C. Mutations of cell cycle regulators-biological and clinical implications for human neoplasia. Am J Pathol 1995; 147: 545-60.
18. Brenner A J, Aldaz C M. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. Cancer Res 1995; 55: 2892-5.
19. van der Riet P, Nawroz H, Hruban R H et al. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 1994; 54: 1156-8.
20. Steiner M S, Wang Y, Zhang Y, Zhang X, Lu Y. p16/MTS1/INK4A suppresses prostate cancer by both pRb dependent and independent pathways. Oncogene 2000; 19: 1297-306.
21. INK4a gene in leiomyosarcoma of soft tissue: Decreased p16 expression correlates with promoter methylation and poor prognosis. J Pathol 2003; 201: 487-95.
22. Serrano M, Hannon G J, Beach B. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-7.
23. NK4A inactivation and telomerase activity are required to immortalized human epithelial cells. Nature 1998; 396: 84-8.
24. Liggett Jr W H, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998; 16: 1197-206.
25. Nobori T, Miura K, Wu D J, Lois A, Takabayashi K, Carson D A. Detections of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753-6.
26. El-Naggar A K, Lai S, Clayman G L et al. Expression of P16, Rb, and Cyclin D1 gene products in oral and laryngeal squamous carcinoma: biological and clinical implications. Hum Pathol 1993; 30: 1013-18.
27. Lukas J, Parry D, Aagaard L et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumor suppressor p16. Nature 1995; 375: 503-6.
28. Herman J G, Graff J R, Myohanen S, Nelkin B D, Baylin S B. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Prog Nat Sci 1996; 93: 9821-6.
29. Nie Y, Liao J, Zhao X et al. Detection of multiple gene hypermethylation in the development of esophageal squamous cell carcinoma. Carcinogenesis 2002; 23: 1713-20.
30. INK4A by CpG hypermethylation is not a frequent event in colorectal cancer. J Surg Oncol 2003; 84: 143-50.
31. Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M, Kelsey K T. Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 2002; 21: 4231-6.
32. INK4A in archival human solid tumors: Correlation with retinoblastoma protein expression. Cancer Res 1995; 55: 6006-11.
33. Takeuchi H, Ozawa S, Ando N et al. Further evidence that altered p16/ CDKN2 gene expression is associated with lymph node metastasis in squamous cell carcinoma of the esophagus. Oncol Rep 2001; 8: 627-32.
34. Herman J G, Merlo A, Mao L et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55: 4525-30.
35. INK4A expression in human breast cancer. Am J Pathol 1996; 149: 15-20.
36. Takeuchi H, Ozawa S, Ando N et al. Altered p16/MTS1/CDKN2 and cyclin D1/ PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus. Clin Cancer Res 1997; 3: 2229-36.
37. INK4 products in primary gastric cancer. Oncology 2000; 58: 126-36.
38. INK4A alleles in neoplasia. Cancer Res 1998; 58: 591-3.